echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Three first-class new drugs in Fujian are approved for market

    Three first-class new drugs in Fujian are approved for market

    • Last Update: 2015-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On May 15, it was learned from the food and Drug Administration of Fujian Province that three first-class new drug varieties of three pharmaceutical enterprises in Fujian Province were approved by the State Food and Drug Administration for listing "These are three national heavyweight drug varieties in our province." Fujian According to the relevant person in charge of the provincial food and drug administration, the three first-class new drug varieties approved for listing are guipaizite maleate (API and injection) of Fujian Jinshan biopharmaceutical Co., Ltd., olmesartan ester (API, tablet and capsule) of Fujian Tianquan Pharmaceutical Co., Ltd and omeprazole sodium bicarbonate capsule of Xiamen Encheng Pharmaceutical Co., Ltd 。
    Among them, the cardiovascular drugs, guipaizite maleate injection is a calcium channel blocker, which is mainly used to treat cardiovascular and cerebrovascular diseases and peripheral vascular diseases It is a drug originally developed by Dilang pharmaceutical factory in Paris, France The product has been withdrawn from the market in France and some countries in Europe, but it is still in use in Japan and South Korea At present, only the raw materials and injection of cinepazide maleate produced by Beijing Sihuan Pharmaceutical Co., Ltd are sold in the market, with an annual sales volume of about 5 billion yuan Olmesartan axetil is an angiotension II receptor antagonist It is the original drug developed by the first three co Pharmaceutical (Shanghai) Co., Ltd and another new antihypertensive drug after valsartan Since it was listed in China in 2006, its sales volume has increased rapidly, showing strong market vitality Omeprazole sodium bicarbonate capsule belongs to PPI, which is the original research drug of santarus company This variety uses sodium bicarbonate to prevent omeprazole from being degraded by gastric acid It can not only inhibit gastric acid, but also make omeprazole absorbed quickly It is convenient to take After taking the medicine, the blood concentration of human body can reach the peak level quickly, and can effectively control gastric acid.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.